PSMA PET Scan: How It Detects Prostate Cancer More Accurately Than Traditional Scans

A rising PSA level, an unclear MRI result or suspected cancer spread can leave an important question unanswered: where exactly is the prostate cancer, and has it spread beyond the prostate? This is where PSMA PET/CT imaging can make a meaningful difference. It helps doctors identify prostate cancer cells that may be difficult to detect using conventional imaging, supporting more accurate prostate cancer detection and staging.

If you or someone you know has been advised to undergo this scan, understanding its benefits can help you make informed decisions about the next steps.

  • Find cancer more precisely: Identify suspicious areas in the prostate, lymph nodes and other parts of the body.
  • Investigate rising PSA levels: Look for possible cancer recurrence after treatment.
  • Guide treatment planning: Help doctors decide whether local treatment or a wider treatment approach is appropriate.

What Is a PSMA PET Scan?

A PSMA PET scan is an advanced imaging test that detects prostate cancer by targeting prostate-specific membrane antigen (PSMA), a protein commonly found on prostate cancer cells. It combines PET and CT to show cancer activity and its location.

During a Ga-68 PSMA PET scan, a radioactive tracer is injected into a vein. The scanner detects its uptake in suspicious areas, helping identify possible cancer spread or recurrence. However, not all uptake indicates cancer, so results must be assessed alongside PSA levels, medical history and other investigations.

Why Is PSMA PET More Accurate Than Traditional Scans?

Traditional imaging remains valuable, but each technique has limitations. CT mainly shows anatomical structures, MRI provides detailed soft-tissue images, and bone scans identify changes associated with bone activity. Small cancer deposits can sometimes remain undetected, particularly when they have not caused obvious structural changes.

PSMA PET adds molecular information, helping doctors identify disease based on tracer uptake rather than relying on size or structural changes alone.

Key advantages of PSMA PET imaging

  • Better detection of small deposits: It can reveal suspicious lymph nodes or distant lesions that do not appear enlarged on a CT scan.
  • More precise disease mapping: It helps identify potential cancer spread beyond the prostate, including to bones, lymph nodes and other sites.
  • Improved assessment of recurrence: It can locate possible recurrent cancer in patients whose PSA levels rise after surgery or radiotherapy.

Research supports the use of PSMA PET in appropriate clinical situations. For example, the randomised proPSMA trial found that PSMA PET/CT was more accurate than conventional CT and bone scanning for staging men with high-risk prostate cancer before treatment. The best imaging test still depends on the patient’s individual circumstances.

PSMA PET vs Traditional Scans: A Quick Comparison

Imaging testMain purposeKey limitation
CT scanShows anatomy and enlarged lymph nodesSmall deposits may be missed
MRIExamines the prostate and surrounding soft tissueMay not detect all distant disease
Bone scanIdentifies bone changes associated with cancerMay miss early disease without significant bone changes
PSMA PET/CTDetects PSMA-related tracer activity and maps its locationSome cancers show low uptake; benign findings can mimic disease

The difference is especially relevant when conventional results are inconclusive. A bone scan vs PSMA PET comparison often favours PSMA PET for detecting prostate cancer spread in suitable patients, although the two tests assess disease differently.

When Do Doctors Recommend a PSMA PET Scan?

PSMA PET is not necessary for every person with prostate cancer. Doctors may recommend it when the results are likely to change diagnosis, staging or treatment decisions.

1. Initial prostate cancer staging

In men recently diagnosed with high-risk prostate cancer, the scan helps determine whether the disease has reached nearby lymph nodes or spread to other parts of the body. This supports more informed prostate cancer staging before treatment begins.

2. Suspected biochemical recurrence

After surgery or radiotherapy, PSA levels may rise even when other scans appear normal. A PSMA PET scan can help investigate this biochemical recurrence and identify where the cancer may have returned.

3. Suspected metastatic disease

When doctors suspect metastatic prostate cancer, PSMA PET may help map disease beyond the prostate and assess whether additional treatment is needed.

The scan’s value lies in answering a specific clinical question, not simply in providing more images.

What Should You Know Before Your Scan?

Understanding PSMA PET scan preparation can make the appointment easier. Your imaging centre will provide instructions based on the tracer and local protocol.

  • Follow the centre’s instructions: Fasting requirements and medication guidance may vary, so confirm them before your appointment.
  • Share your medical history: Tell the team about previous prostate cancer treatment, current medicines and relevant medical conditions.
  • Allow enough time: The tracer needs time to distribute through the body before imaging begins. The appointment may take several hours overall, although the scan itself is usually shorter.
  • Discuss radiation exposure: The test uses a small amount of radioactive tracer and CT radiation. Your doctor can explain the benefits and risks for your situation.

Most patients can return to normal activities afterwards, subject to the imaging centre’s advice.

Cost, Referrals and Finding a Scan Centre

The PSMA PET scan cost depends on the tracer used, imaging centre and additional services. When searching for a PSMA PET scan near me, check the centre’s expertise, availability, referral requirements and report turnaround time.

Book Your PSMA PET Scan

If your PSA levels are rising or your existing scans are inconclusive, consult your specialist about the next steps. Contact Picture This by Jankharia to enquire about scan availability, costs and preparation requirements. Book your scan at the earliest opportunity to give your doctor clearer insights for planning the most appropriate treatment.

Frequently Asked Questions

PSMA PET/CT and MRI provide different types of information. MRI provides detailed images of the prostate and surrounding tissues, whereas PSMA PET/CT can help detect cancer that may have spread to other parts of the body.

  • Local tumour assessment: MRI offers detailed views of the prostate.
  • Whole-body assessment: PSMA PET/CT can help identify suspicious lymph nodes and distant deposits.
  • Combined approach: Doctors may use both tests when their findings complement each other.

The preferred investigation depends on the clinical question and the patient’s risk profile.

A PSMA PET scan can detect some prostate cancer deposits that conventional imaging misses, but it is not the standard screening test for every man with suspected early-stage disease.

  • PSA testing: Helps identify men who may need further assessment.
  • Prostate MRI and biopsy: Often play central roles in diagnosing localised cancer.
  • Molecular imaging: May be recommended when staging or other clinical findings justify it.

A specialist can determine whether advanced imaging is appropriate.

A positive result means that one or more areas show tracer uptake considered suspicious on the scan. It does not automatically confirm that every highlighted area contains cancer.

  • Lymph node findings: May indicate possible regional spread.
  • Bone or organ findings: May require assessment for metastatic disease.
  • Clinical correlation: PSA levels, previous treatment and other imaging help establish the likely diagnosis.

Your radiologist and treating specialist should interpret the findings together.

PSMA PET/CT can identify recurrent prostate cancer in some patients with low PSA levels. However, detection becomes less reliable when PSA is very low, and results depend on tumour biology and the tracer used.

  • PSA trend: A consistent rise can prompt further investigation.
  • Previous treatment: Surgery and radiotherapy influence how recurrence is assessed.
  • Timing: Your specialist can advise when imaging is most likely to provide useful information.

A negative scan does not completely exclude recurrent disease.

A gallium-68 PSMA examination uses a small amount of radioactive tracer. The overall radiation exposure includes the CT component and should be considered in the context of the expected diagnostic benefit.

  • Radiation dose: Ask the imaging team about the expected exposure.
  • Medical history: Inform staff about relevant conditions and medicines.
  • After the scan: Follow the centre’s advice on hydration and routine activities.

Your doctor can explain whether the benefits outweigh the risks in your case.